A doctor and a patient connecting over the one-time-only infusion of ZOLGENSMA

The one-time-only dose to stop SMA progression

ZOLGENSMA® (onasemnogene abeparvovec-xioi)  is a gene therapy for pediatric patients less than 2 years of age with spinal muscular atrophy (SMA)1

Getting started with ZOLGENSMA

Complete the ZOLGENSMA Prescription and Patient Consent Forms for eligible patients to help with insurance and prescription-related processes.

ZOLGENSMA Prescription and Patient Consent Forms

Download

ONEGENE PROGRAM

Patient support

The OneGene Program™, offered by AveXis, is a comprehensive, individualized support program for families with pediatric patients less than 2 years of age with spinal muscular atrophy (SMA) and their healthcare providers throughout the ZOLGENSMA treatment journey.

OneGene Program support includes:
  • Answers to questions about ZOLGENSMA
  • A dedicated, personalized support team focused on the needs of each family
  • Verification of insurance benefits
  • Coordination of financial assistance programs for eligible patients

Families can access the full range of OneGene Program support resources when the ZOLGENSMA Prescription Form and accompanying Patient Consent Form have been provided to the OneGene Program.

For questions call 1-855-441-GENE (4363),
Monday-Friday (8 AM to 8 PM ET)

For questions call 1-855-441-GENE (4363) – Monday-Friday (8 AM to 8 PM ET)

Discover more about ZOLGENSMA

About ZOLGENSMA

Explore efficacy, safety, dosing, and how ZOLGENSMA works

Understand SMA

Learn about the signs and symptoms of SMA

Steps to Treatment

What to know before, during, and after infusion day

Resources

Learn about resources available to your patients

Reference: 1. ZOLGENSMA [prescribing information]. Bannockburn, IL: AveXis, Inc; 2019.